JP7535791B2 - 肺炎球菌融合タンパク質ワクチン - Google Patents

肺炎球菌融合タンパク質ワクチン Download PDF

Info

Publication number
JP7535791B2
JP7535791B2 JP2021513863A JP2021513863A JP7535791B2 JP 7535791 B2 JP7535791 B2 JP 7535791B2 JP 2021513863 A JP2021513863 A JP 2021513863A JP 2021513863 A JP2021513863 A JP 2021513863A JP 7535791 B2 JP7535791 B2 JP 7535791B2
Authority
JP
Japan
Prior art keywords
seq
fusion protein
polypeptide
vaccine
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021513863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500409A (ja
JP2022500409A5 (enExample
Inventor
リチャード マリー，
インジェ ルー，
ファン ジャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2022500409A publication Critical patent/JP2022500409A/ja
Publication of JP2022500409A5 publication Critical patent/JP2022500409A5/ja
Priority to JP2024077967A priority Critical patent/JP2024096456A/ja
Application granted granted Critical
Publication of JP7535791B2 publication Critical patent/JP7535791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021513863A 2018-09-12 2019-09-12 肺炎球菌融合タンパク質ワクチン Active JP7535791B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077967A JP2024096456A (ja) 2018-09-12 2024-05-13 肺炎球菌融合タンパク質ワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730199P 2018-09-12 2018-09-12
US62/730,199 2018-09-12
PCT/US2019/050800 WO2020056127A1 (en) 2018-09-12 2019-09-12 Pneumococcal fusion protein vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077967A Division JP2024096456A (ja) 2018-09-12 2024-05-13 肺炎球菌融合タンパク質ワクチン

Publications (3)

Publication Number Publication Date
JP2022500409A JP2022500409A (ja) 2022-01-04
JP2022500409A5 JP2022500409A5 (enExample) 2022-09-21
JP7535791B2 true JP7535791B2 (ja) 2024-08-19

Family

ID=69772826

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513863A Active JP7535791B2 (ja) 2018-09-12 2019-09-12 肺炎球菌融合タンパク質ワクチン
JP2024077967A Pending JP2024096456A (ja) 2018-09-12 2024-05-13 肺炎球菌融合タンパク質ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077967A Pending JP2024096456A (ja) 2018-09-12 2024-05-13 肺炎球菌融合タンパク質ワクチン

Country Status (13)

Country Link
US (3) US20200087361A1 (enExample)
EP (1) EP3849599A4 (enExample)
JP (2) JP7535791B2 (enExample)
KR (1) KR102922338B1 (enExample)
CN (1) CN113164580B (enExample)
AU (1) AU2019338448B2 (enExample)
BR (1) BR112021004185A2 (enExample)
CA (1) CA3111436A1 (enExample)
IL (1) IL281203A (enExample)
MX (1) MX2021002909A (enExample)
SG (1) SG11202101973YA (enExample)
TW (1) TWI852943B (enExample)
WO (1) WO2020056127A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines
AU2023283913A1 (en) * 2022-06-07 2024-10-31 Peking University First Hospital Fusion protein containing truncated iga protease and use thereof
WO2024138144A1 (en) * 2022-12-22 2024-06-27 The Medical College Of Wisconsin, Inc. Compositions that target cd138 and cd3 and methods of making and using the same
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505415A (ja) 1996-10-31 2001-04-24 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
JP2002521058A (ja) 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
JP2014517835A (ja) 2011-05-11 2014-07-24 チルドレンズ メディカル センター コーポレーション 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
JP2016509011A (ja) 2013-02-07 2016-03-24 チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
WO2017192801A1 (en) 2016-05-04 2017-11-09 The Children's Medical Center Corporation Methods to purify avidin-like proteins and fusion proteins thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
AU712981B2 (en) 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US6087328A (en) 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6287568B1 (en) 1997-09-09 2001-09-11 The Trustees Of Columbia University In The City Of New York Methods relating to immunogenic dextran-protein conjugates
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CN1816350B (zh) 2002-05-14 2010-11-10 莱顿大学 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP2333114A1 (en) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
BRPI0410423A (pt) 2003-05-07 2006-06-06 Sanofi Pasteur Inc processo de imunogenicidade melhorada para vacinação meningocócica
EP1670509A4 (en) 2003-09-03 2007-10-31 Dendritherapeutics Inc MULTIPLEX VACCINES
US7556814B2 (en) 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
WO2005103073A2 (en) 2004-04-27 2005-11-03 Intercell Ag Td antigens
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
EP1791961B1 (en) 2004-08-18 2011-06-08 The Governors of the University of Alberta Protein production method utilizing yebf
FI20041396A0 (fi) 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
KR20070122458A (ko) 2005-02-11 2007-12-31 에이스 바이오사이언시즈 에이/에스 표재성 스트렙토코커스 뉴모니아 폴리펩티드
US20090148894A1 (en) 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
EP2308504A3 (en) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
CA2627446A1 (en) * 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
JP2009518427A (ja) 2005-12-08 2009-05-07 ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド Ｉｎｖｉｖｏ細胞表面操作
WO2007081583A2 (en) 2006-01-04 2007-07-19 Children's Medical Center Corporation Anti-pneumococcal preparations and methods of use
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
WO2007149982A2 (en) 2006-06-22 2007-12-27 The Brigham And Women's Hospital, Inc. Diagnosis of autoimmune disease
CA2690973A1 (en) 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
WO2008152448A2 (en) 2006-12-21 2008-12-18 Emergent Product Development Uk Limited Streptococcus proteins, and their use in vaccination
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
CA2677179C (en) 2007-01-31 2016-02-16 Dow Global Technologies Inc. Bacterial leader sequences for increased expression
CA2683748C (en) 2007-04-13 2016-02-16 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009021548A1 (en) 2007-08-10 2009-02-19 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
CN102712680B (zh) 2008-12-24 2016-06-22 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN107126557A (zh) 2009-06-29 2017-09-05 健诺西生物科学公司 抗肺炎链球菌的疫苗和组合物
CN101797381B (zh) 2010-01-29 2012-05-23 中国人民解放军第三军医大学 乙肝病毒抗原与路易斯寡糖的复合物及其制备方法和应用
EP2563396A2 (en) 2010-04-30 2013-03-06 Augmenta Biologicals LLC Delivery proteins
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
IL281204B2 (en) * 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505415A (ja) 1996-10-31 2001-04-24 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
JP2002521058A (ja) 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
JP2014517835A (ja) 2011-05-11 2014-07-24 チルドレンズ メディカル センター コーポレーション 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
JP2016509011A (ja) 2013-02-07 2016-03-24 チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
WO2017192801A1 (en) 2016-05-04 2017-11-09 The Children's Medical Center Corporation Methods to purify avidin-like proteins and fusion proteins thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fan Zhang et al.，PNAS，2013年，Vol. 110, No. 33，pp. 13564-13569
Zhen Gong et al.，PLOS ONE，2015年，Vol. 10, No. 8, Article No. e0136507

Also Published As

Publication number Publication date
MX2021002909A (es) 2021-09-08
SG11202101973YA (en) 2021-03-30
CN113164580B (zh) 2025-06-10
US20230089151A1 (en) 2023-03-23
JP2024096456A (ja) 2024-07-12
EP3849599A4 (en) 2022-06-29
AU2019338448B2 (en) 2026-02-26
US12129283B2 (en) 2024-10-29
CA3111436A1 (en) 2020-03-19
BR112021004185A2 (pt) 2021-05-25
US20200087361A1 (en) 2020-03-19
US20250019407A1 (en) 2025-01-16
KR102922338B1 (ko) 2026-02-05
IL281203A (en) 2021-04-29
AU2019338448A1 (en) 2021-05-06
CN113164580A (zh) 2021-07-23
KR20210088535A (ko) 2021-07-14
TWI852943B (zh) 2024-08-21
EP3849599A1 (en) 2021-07-21
TW202035436A (zh) 2020-10-01
JP2022500409A (ja) 2022-01-04
WO2020056127A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
US12370247B2 (en) Multivalent pneumococcal vaccines
US12129283B2 (en) Pneumococcal fusion protein vaccines
US12377140B2 (en) Multivalent pneumococcal vaccines
US20250064910A1 (en) A maps vaccine targeting salmonella enterica serovars
EP4727575A2 (en) Fusion proteins generating protective antibodies and protective th17 responses for pseudomonas aeruginosa
EP4601683A1 (en) A maps vaccine targeting group b streptococcus (gbs)
WO2024192346A1 (en) Immunogenic compositions
WO2023192997A2 (en) Immunogenic compositions for b-cell recall response to a polysaccharide antigen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240730

R150 Certificate of patent or registration of utility model

Ref document number: 7535791

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150